Get started
Author

Maria Alessandra Calegari

Observed names: A. Calegari, Alessandra Calegari, Calegari, Maria Alessandra, M A Calegari, M. A. Calegari, M. Calegari, M.A. Calegari, Maria A. Calegari, Maria Calegari
ORCID: 0000-0001-6856-2593
Observed ORCID: 0000-0001-6856-2593
OpenAlex ID: A5016773277
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
2022 · Federica Morano, Alessandra Raimondi, et al. · Journal of Clinical Oncology · 132
PDF
PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target
2019 · Lisa Salvatore, Maria Alessandra Calegari, et al. · Cancers · 86
PDF
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
2021 · Ina Valeria Zurlo, Mattia Schino, et al. · Cancer Immunology Immunotherapy · 80
PDF
A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study
2019 · Fotios Loupakis, Rossana Intini, et al. · European Journal of Cancer · 69
PDF
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
2017 · M A Calegari, A Inno, et al. · British Journal of Cancer · 55
PDF
Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature
2019 · Pietro Sollena, Maria Mannino, et al. · Drugs in Context · 38
PDF
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report
2015 · A. Orlandi, R. Fasciani, et al. · BMC Cancer · 38
PDF
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance
2024 · A. Esposito, A. Agostini, et al. · Cell Death and Disease · 29
PDF
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
2016 · A. Orlandi, M. A. Calegari, et al. · Clinical & Translational Oncology · 29
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
2012 · M Basso, A Strippoli, et al. · British Journal of Cancer · 28
PDF
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
2020 · Ina Valeria Zurlo, Michele Basso, et al. · Cancers · 24
PDF
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
2020 · Alessandro Parisi, Alessio Cortellini, et al. · Cancers · 21
PDF
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases
2020 · Michele Basso, Salvatore Corallo, et al. · Scientific Reports · 20
PDF
BRAF in Metastatic Colorectal Cancer: The Future Starts Now
2015 · Armando Orlandi, Maria Alessandra Calegari, et al. · Pharmacogenomics · 20
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
2014 · A. Orlandi, M. Di Salvatore, et al. · Journal of Cancer · 20
PDF
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
2024 · Carmine Pinto, Armando Orlandi, et al. · Journal of Clinical Oncology · 19
PDF
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
2025 · C. Antoniotti, M. Carullo, et al. · ESMO Open · 15
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
2022 · Roberto Moretto, Andrew Elliott, et al. · British Journal of Cancer · 14
PDF
Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection
2021 · Francesco Ardito, Francesco Razionale, et al. · Cancers · 14
PDF
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
2023 · Carlo Signorelli, Maria Alessandra Calegari, et al. · Current Oncology · 13
PDF
Diagnosis and management of breast lymphoma: a single-institution retrospective analysis
2018 · Armando Orlandi, Alejandro Martin Sanchez, et al. · Translational Cancer Research · 13
PDF
Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer
2021 · Andrea Di Giorgio, Francesco Santullo, et al. · Journal of Gastrointestinal Surgery · 11
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)
2021 · Maria Alessandra Calegari, Lisa Salvatore, et al. · Cancers · 11
PDF
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase
2018 · Sarit Schwartz, Chris Szeto, et al. · European Journal of Cancer · 11
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis
2023 · Luca Mastrantoni, Viria Beccia, et al. · Critical Reviews in Oncology/Hematology · 8
Works count: 163
Citation count: 940
H-index: 16
I10-index: 24
Year
Topic
Type